Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements

Molecular and Cellular Biochemistry

Volumn 408, Issue 1-2, 2015, Pages 89-102

  Sajadimajd, Soraya ^a   Yazdanparast, Razieh ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

HER2; Menadione; Notch1; Oxidative stress; SKBR3 cells; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUTATHIONE; MENADIONE; NOTCH1 RECEPTOR; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR HES 1; TRASTUZUMAB; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIZATION; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC50; UPREGULATION; WOUND HEALING; BREAST NEOPLASMS; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; TRASTUZUMAB; VITAMIN K 3;

EID: 84941996023     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2485-0     Document Type: Article

References (46)

1. Sørlie T et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98(19):10869–10874
2. Eroles P et al (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 38(6):698–707
3. Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232(2):123–138
4. Romond EH et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684
5. Buzdar AU et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676–3685
6. Nahta R et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5):269–280
7. Osipo C et al (2008) ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene 27(37):5019–5032
8. Krebs LT et al (2000) Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 14(11):1343–1352
9. Wang J et al (2011) Notch1 is involved in migration and invasion of human breast cancer cells. Oncol Rep 26(5):1295
10. Simmons MJ et al (2012) NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res 14(5):R126
11. Kim TH et al (2014) Silibinin induces cell death through reactive oxygen species-dependent downregulation of Notch-1/ERK/Akt signaling in human breast cancer cells. J Pharmacol Exp Ther 349(2):268–278
12. Benhar M, Engelberg D, Levitzki A (2002) ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 3(5):420–425
13. Martindale JL, Holbrook NJ (2002) Cellular response to oxidative stress: signaling for suicide and survival*. J Cell Physiol 192(1):1–15
14. Poli G et al (2004) Oxidative stress and cell signalling. Curr Med Chem 11(9):1163–1182
15. Pelicano H, Carney D, Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updates 7(2):97–110
16. Matsura T et al (1999) Hydrogen peroxide-induced apoptosis in HL-60 cells requires caspase-3 activation. Free Radical Res 30(1):73–83
17. Yamakawa H et al (2000) Activation of caspase-9 and-3 during H2O2-induced apoptosis of PC12 cells independent of ceramide formation. Neurol Res 22(6):556–564
18. Yokomizo A et al (1995) Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55(19):4293–4296
19. ® for the treatment of prostate cancer patients who have failed standard therapy. Int J Med Sci 5(2):62
20. Akiyoshi T et al (2009) The potential of vitamin K3 as an anticancer agent against breast cancer that acts via the mitochondria-related apoptotic pathway. Cancer Chemother Pharmacol 65(1):143–150
21. Liao W, Wu F, Wu C (2000) Binary/ternary combined effects of vitamin K3 with other antitumor agents in nasopharyngeal carcinoma CG1 cells. Int J Oncol 17(2):323–331
22. Margolin KA et al (1995) Phase I study of mitomycin C and menadione in advanced solid tumors. Cancer Chemother Pharmacol 36(4):293–298
23. Tetef M et al (1995) Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. Invest New Drugs 13(2):157–162
24. Vistica DT et al (1991) Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res 51(10):2515–2520
25. Chou T-C, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55
26. LeBel CP, Ischiropoulos H, Bondy SC (1992) Evaluation of the probe 2’, 7’-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 5(2):227–231
27. Meshkini A, Yazdanparast R (2008) Involvement of ERK/MAPK pathway in megakaryocytic differentiation of K562 cells induced by 3-hydrogenkwadaphnin. Toxicol In Vitro 22(6):1503–1510
28. Liang K et al (2003) Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2(11):1113–1120
29. Lowry OH et al (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265–275
30. Kinnula VL, Crapo JD (2004) Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 36(6):718–744
31. Estrela JM, Ortega A, Obrador E (2006) Glutathione in cancer biology and therapy. Crit Rev Clin Lab Sci 43(2):143–181
32. Fang J, Nakamura H, Iyer A (2007) Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 15(7–8):475–486
33. Timolati F et al (2006) Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation–contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 41(5):845–854
34. Gordon LI et al (2009) Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 284(4):2080–2087
35. Dogan I et al (2011) Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Mol Cell Biochem 347(1–2):41–51
36. Aird KM et al (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132(1):109–119
37. Victorino VJ et al (2014) Overexpression of HER-2/neu protein attenuates the oxidative systemic profile in women diagnosed with breast cancer. Tumor Biol 35(4):3025–3034
38. Seidman AD et al (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19(10):2587–2595
39. Raff JP et al (2004) Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 4(6):420–427
40. Boonstra J, Post JA (2004) Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene 337:1–13
41. Kim S-J et al (2005) Glucose-dependent insulinotropic polypeptide (GIP) stimulation of pancreatic β-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280(23):22297–22307
42. Boreddy SR, Pramanik KC, Srivastava SK (2011) Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3 K/AKT/FOXO pathway. Clin Cancer Res 17(7):1784–1795
43. Chakrabarty A et al (2013) Trastuzumab-resistant cells rely on a HER2-PI3 K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res 73(3):1190–1200
44. Mittal S et al (2009) Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis. Mol Cancer 8(1):128
45. Efferson CL et al (2010) Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 70(6):2476–2484
46. Meurette O et al (2009) Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 69(12):5015–5022